Global Prostate Cancer Vaccines Market Research Report 2021

1 Prostate Cancer Vaccines Market Overview

• 1.1 Product Overview and Scope of Prostate Cancer Vaccines
• 1.2 Prostate Cancer Vaccines Segment by Type
  • 1.2.1 Global Prostate Cancer Vaccines Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Tablet
  • 1.2.3 Injection
• 1.3 Prostate Cancer Vaccines Segment by Application
  • 1.3.1 Prostate Cancer Vaccines Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Others
• 1.4 Global Prostate Cancer Vaccines Market Size Estimates and Forecasts
  • 1.4.1 Global Prostate Cancer Vaccines Revenue 2016-2027
  • 1.4.2 Global Prostate Cancer Vaccines Sales 2016-2027
  • 1.4.3 Prostate Cancer Vaccines Market Size by Region: 2016 Versus 2021 Versus 2027

2 Prostate Cancer Vaccines Market Competition by Manufacturers

• 2.1 Global Prostate Cancer Vaccines Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Prostate Cancer Vaccines Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Prostate Cancer Vaccines Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Prostate Cancer Vaccines Manufacturing Sites, Area Served, Product Type
• 2.5 Prostate Cancer Vaccines Market Competitive Situation and Trends
  • 2.5.1 Prostate Cancer Vaccines Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Prostate Cancer Vaccines Players Market Share by Revenue
  • 2.5.3 Global Prostate Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Prostate Cancer Vaccines Retrospective Market Scenario by Region

• 3.1 Global Prostate Cancer Vaccines Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Prostate Cancer Vaccines Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Prostate Cancer Vaccines Market Facts & Figures by Country
  • 3.3.1 North America Prostate Cancer Vaccines Sales by Country
  • 3.3.2 North America Prostate Cancer Vaccines Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Prostate Cancer Vaccines Market Facts & Figures by Country
  • 3.4.1 Europe Prostate Cancer Vaccines Sales by Country
  • 3.4.2 Europe Prostate Cancer Vaccines Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Prostate Cancer Vaccines Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Prostate Cancer Vaccines Sales by Region
  • 3.5.2 Asia Pacific Prostate Cancer Vaccines Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Prostate Cancer Vaccines Market Facts & Figures by Country
  • 3.6.1 Latin America Prostate Cancer Vaccines Sales by Country
  • 3.6.2 Latin America Prostate Cancer Vaccines Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Prostate Cancer Vaccines Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Prostate Cancer Vaccines Sales by Country
  • 3.7.2 Middle East and Africa Prostate Cancer Vaccines Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Prostate Cancer Vaccines Historic Market Analysis by Type

• 4.1 Global Prostate Cancer Vaccines Sales Market Share by Type (2016-2021)
• 4.2 Global Prostate Cancer Vaccines Revenue Market Share by Type (2016-2021)
• 4.3 Global Prostate Cancer Vaccines Price by Type (2016-2021)

5 Global Prostate Cancer Vaccines Historic Market Analysis by Application

• 5.1 Global Prostate Cancer Vaccines Sales Market Share by Application (2016-2021)
• 5.2 Global Prostate Cancer Vaccines Revenue Market Share by Application (2016-2021)
• 5.3 Global Prostate Cancer Vaccines Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Dendreon Corporation
  • 6.1.1 Dendreon Corporation Corporation Information
  • 6.1.2 Dendreon Corporation Description and Business Overview
  • 6.1.3 Dendreon Corporation Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Dendreon Corporation Product Portfolio
  • 6.1.5 Dendreon Corporation Recent Developments/Updates
• 6.2 Bavarian Nordic
  • 6.2.1 Bavarian Nordic Corporation Information
  • 6.2.2 Bavarian Nordic Description and Business Overview
  • 6.2.3 Bavarian Nordic Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Bavarian Nordic Product Portfolio
  • 6.2.5 Bavarian Nordic Recent Developments/Updates
• 6.3 Advantagene
  • 6.3.1 Advantagene Corporation Information
  • 6.3.2 Advantagene Description and Business Overview
  • 6.3.3 Advantagene Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Advantagene Product Portfolio
  • 6.3.5 Advantagene Recent Developments/Updates
• 6.4 OncBioMune Pharmaceuticals
  • 6.4.1 OncBioMune Pharmaceuticals Corporation Information
  • 6.4.2 OncBioMune Pharmaceuticals Description and Business Overview
  • 6.4.3 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 OncBioMune Pharmaceuticals Product Portfolio
  • 6.4.5 OncBioMune Pharmaceuticals Recent Developments/Updates
• 6.5 Advaxis immunotherapies
  • 6.5.1 Advaxis immunotherapies Corporation Information
  • 6.5.2 Advaxis immunotherapies Description and Business Overview
  • 6.5.3 Advaxis immunotherapies Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Advaxis immunotherapies Product Portfolio
  • 6.5.5 Advaxis immunotherapies Recent Developments/Updates
• 6.6 SOTIO
  • 6.6.1 SOTIO Corporation Information
  • 6.6.2 SOTIO Description and Business Overview
  • 6.6.3 SOTIO Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 SOTIO Product Portfolio
  • 6.6.5 SOTIO Recent Developments/Updates
• 6.7 Cleveland BioLabs Inc.
  • 6.6.1 Cleveland BioLabs Inc. Corporation Information
  • 6.6.2 Cleveland BioLabs Inc. Description and Business Overview
  • 6.6.3 Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Cleveland BioLabs Inc. Product Portfolio
  • 6.7.5 Cleveland BioLabs Inc. Recent Developments/Updates
• 6.8 Curevac AG
  • 6.8.1 Curevac AG Corporation Information
  • 6.8.2 Curevac AG Description and Business Overview
  • 6.8.3 Curevac AG Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Curevac AG Product Portfolio
  • 6.8.5 Curevac AG Recent Developments/Updates
• 6.9 Mediolanum Farmaceutici
  • 6.9.1 Mediolanum Farmaceutici Corporation Information
  • 6.9.2 Mediolanum Farmaceutici Description and Business Overview
  • 6.9.3 Mediolanum Farmaceutici Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Mediolanum Farmaceutici Product Portfolio
  • 6.9.5 Mediolanum Farmaceutici Recent Developments/Updates
• 6.10 Pfizer Inc.
  • 6.10.1 Pfizer Inc. Corporation Information
  • 6.10.2 Pfizer Inc. Description and Business Overview
  • 6.10.3 Pfizer Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Pfizer Inc. Product Portfolio
  • 6.10.5 Pfizer Inc. Recent Developments/Updates
• 6.11 Vaccitech
  • 6.11.1 Vaccitech Corporation Information
  • 6.11.2 Vaccitech Prostate Cancer Vaccines Description and Business Overview
  • 6.11.3 Vaccitech Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Vaccitech Product Portfolio
  • 6.11.5 Vaccitech Recent Developments/Updates
• 6.12 Sensei Biotherapeutics
  • 6.12.1 Sensei Biotherapeutics Corporation Information
  • 6.12.2 Sensei Biotherapeutics Prostate Cancer Vaccines Description and Business Overview
  • 6.12.3 Sensei Biotherapeutics Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Sensei Biotherapeutics Product Portfolio
  • 6.12.5 Sensei Biotherapeutics Recent Developments/Updates
• 6.13 Medigene AG
  • 6.13.1 Medigene AG Corporation Information
  • 6.13.2 Medigene AG Prostate Cancer Vaccines Description and Business Overview
  • 6.13.3 Medigene AG Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 Medigene AG Product Portfolio
  • 6.13.5 Medigene AG Recent Developments/Updates
• 6.14 Ultimovacs
  • 6.14.1 Ultimovacs Corporation Information
  • 6.14.2 Ultimovacs Prostate Cancer Vaccines Description and Business Overview
  • 6.14.3 Ultimovacs Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 Ultimovacs Product Portfolio
  • 6.14.5 Ultimovacs Recent Developments/Updates
• 6.15 Oncovir Inc.
  • 6.15.1 Oncovir Inc. Corporation Information
  • 6.15.2 Oncovir Inc. Prostate Cancer Vaccines Description and Business Overview
  • 6.15.3 Oncovir Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.15.4 Oncovir Inc. Product Portfolio
  • 6.15.5 Oncovir Inc. Recent Developments/Updates
• 6.16 UbiVac
  • 6.16.1 UbiVac Corporation Information
  • 6.16.2 UbiVac Prostate Cancer Vaccines Description and Business Overview
  • 6.16.3 UbiVac Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.16.4 UbiVac Product Portfolio
  • 6.16.5 UbiVac Recent Developments/Updates
• 6.17 Momotaro-Gene Inc.
  • 6.17.1 Momotaro-Gene Inc. Corporation Information
  • 6.17.2 Momotaro-Gene Inc. Prostate Cancer Vaccines Description and Business Overview
  • 6.17.3 Momotaro-Gene Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.17.4 Momotaro-Gene Inc. Product Portfolio
  • 6.17.5 Momotaro-Gene Inc. Recent Developments/Updates
• 6.18 Vaccibody AS
  • 6.18.1 Vaccibody AS Corporation Information
  • 6.18.2 Vaccibody AS Prostate Cancer Vaccines Description and Business Overview
  • 6.18.3 Vaccibody AS Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.18.4 Vaccibody AS Product Portfolio
  • 6.18.5 Vaccibody AS Recent Developments/Updates
• 6.19 AlphaVax Inc.
  • 6.19.1 AlphaVax Inc. Corporation Information
  • 6.19.2 AlphaVax Inc. Prostate Cancer Vaccines Description and Business Overview
  • 6.19.3 AlphaVax Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.19.4 AlphaVax Inc. Product Portfolio
  • 6.19.5 AlphaVax Inc. Recent Developments/Updates

7 Prostate Cancer Vaccines Manufacturing Cost Analysis

• 7.1 Prostate Cancer Vaccines Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Prostate Cancer Vaccines
• 7.4 Prostate Cancer Vaccines Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Prostate Cancer Vaccines Distributors List
• 8.3 Prostate Cancer Vaccines Customers

9 Prostate Cancer Vaccines Market Dynamics

• 9.1 Prostate Cancer Vaccines Industry Trends
• 9.2 Prostate Cancer Vaccines Growth Drivers
• 9.3 Prostate Cancer Vaccines Market Challenges
• 9.4 Prostate Cancer Vaccines Market Restraints

10 Global Market Forecast

• 10.1 Prostate Cancer Vaccines Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Prostate Cancer Vaccines by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Prostate Cancer Vaccines by Type (2022-2027)
• 10.2 Prostate Cancer Vaccines Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Prostate Cancer Vaccines by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Prostate Cancer Vaccines by Application (2022-2027)
• 10.3 Prostate Cancer Vaccines Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Prostate Cancer Vaccines by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Prostate Cancer Vaccines by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List